Furui Medical plans H-share listing, invests in equity fund

Inner Mongolia Furui Medical Science (Furui Medical) announced plans to issue H-shares and list them on the Main Board of The Stock Exchange of Hong Kong Limited to enhance competitiveness and diversify financing. This move, approved by the board on December 16, 2025, is subject to shareholder approval and regulatory review.

Concurrently, the company will participate in a private equity investment fund, Sichuan Chengde High-tech Innovation Equity Investment Fund (Limited Partnership), committing up to yuan 93 million. This fund, managed by Beijing Yamei Hezhong Investment Management Co., Ltd., will focus on strategic emerging industries, including biomedicine and health tech.

As part of these strategic initiatives, Furui Medical plans to change its securities short name to "Furui Medical Science," effective December 18, 2025, to better reflect its strategic positioning and core business. The company also intends to amend its articles of association and other internal governance documents to align with the requirements for an H-share listing. Deloitte Touche Tohmatsu will be appointed as the auditor for the H-share issuance and listing.